0001764013-23-000153.txt : 20231205
0001764013-23-000153.hdr.sgml : 20231205
20231205162533
ACCESSION NUMBER: 0001764013-23-000153
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20231201
FILED AS OF DATE: 20231205
DATE AS OF CHANGE: 20231205
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: MIGAUSKY GEORGE V
CENTRAL INDEX KEY: 0001134365
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38906
FILM NUMBER: 231466937
MAIL ADDRESS:
STREET 1: C/O DYAX CORP.
STREET 2: 300 TECHNOLOGY SQUARE
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Immunovant, Inc.
CENTRAL INDEX KEY: 0001764013
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 832771572
STATE OF INCORPORATION: DE
FISCAL YEAR END: 0331
BUSINESS ADDRESS:
STREET 1: 320 WEST 37TH STREET
CITY: NEW YORK
STATE: NY
ZIP: 10018
BUSINESS PHONE: 917-580-3099
MAIL ADDRESS:
STREET 1: 320 WEST 37TH STREET
CITY: NEW YORK
STATE: NY
ZIP: 10018
FORMER COMPANY:
FORMER CONFORMED NAME: Health Sciences Acquisitions Corp
DATE OF NAME CHANGE: 20190108
4
1
wk-form4_1701811523.xml
FORM 4
X0508
4
2023-12-01
0
0001764013
Immunovant, Inc.
IMVT
0001134365
MIGAUSKY GEORGE V
320 W 37TH STREET, 6TH FLOOR
NEW YORK
NY
10018
1
0
0
0
1
Common Stock
2023-12-01
4
S
0
4200
38.79
D
118308
D
Common Stock
2023-12-01
4
S
0
3478
39.81
D
114830
D
Common Stock
2023-12-01
4
S
0
5022
40.46
D
109808
D
Represents the sale of shares of common stock pursuant to a Rule 10b5-1 trading plan adopted on May 24, 2023, in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of the above award of restricted stock covering shares of common stock and does not represent a discretionary sale by the reporting person.
The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $38.20 - $39.19 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote to this Form 4.
The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $39.20 - $40.13 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote to this Form 4.
The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $40.20 - $40.60 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote to this Form 4.
/s/ Eva Renee Barnett, attorney-in-fact for George V. Migausky
2023-12-05